check quantity

ProSense 680 Fluorescent Imaging Agent

Proteases perform a fundamental role in protein regulation. Altered activity of lysosomal cathepsins, a class of protease, can indicate many disease-related processes, such as those involved in cancer, inflammation, arthritis, cardiovascular and many others. The ability to detect and quantify normal as well as altered protease cathepsin activity in vivo allows the progress and severity of these disease states to be tracked and interrogated over time. PerkinElmer’s ProSense® imaging agents are protease activatable NIR fluorescent probes that are optically silent in their intact state and become highly fluorescent following protease-mediated cleavage and activation. ProSense is available in 3 formats; 680, 750 EX, and 750 FAST.

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
SKU Display Name
List Price
Your Price
ProSense 680 Fluorescent Imaging Agent
619.00 USD
ProSense 750 EX Fluorescent Imaging Agent
662.00 USD
ProSense 750 FAST Fluorescent Imaging Agent
731.00 USD
Buy Now

Please enter valid quantity

Please log in to add favorites.



ProSense 680 is our original “Smart” cathepsin probe; rather than targeting all protease, smart probes become fluorescent only after enzymatic cleavage, which keeps background down and allows detection of activated protease. 24h imaging at 680 nm.


Fluorescent Agent Type Activatable
Optical Imaging Classification Fluorescence Imaging
Product Brand Name ProSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Application Note

In Vivo Imaging of Atherosclerosis Disease Using FMT

Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).

Noninvasive In Vivo Quantitation of Asthma Severity Using FMT

Asthma is an inflammatory disease process characterized by reversible airway obstruction and airway hyperresponsiveness. This disease process is driven by activated T lymphocytes and eosinophils that are recruited to the lung upon inhalation of triggering allergens. These cells release inflammatory mediators, activate mast cells and epithelial cells and stimulate mucus secretion, ultimately leading to airway obstruction. The incidence and severity of asthma is increasing worldwide, elevating the need for clinically relevant in vivo animal models that can be used to improve the understanding of asthma biology and the development of effective therapeutics. Here we illustrate the use of PerkinElmer’s FMT® 2500LX Quantitative Pre-clinical Imaging System in combination with ProSense® 680 Fluorescent Pre-clinical Imaging Agent, a near-infrared, protease-activatable agent, for the noninvasive in vivo imaging and quantitation of pulmonary inflammation.

PDF 488 KB


In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.



Non-Invasive Near-Infrared Fluorescence Quantitative Tomography (FMT™) of the Effects of PDE4 Inhibitor Therapy in an LPS Murine Model of COPD In Vivo

We demonstrated the ability of the FMT 2500™ in vivo imaging system in combination with two different imaging agents, AngioSense® and ProSense®, to non-invasively visualize and quantify both pulmonary edema and neutrophil protease activity respectively, induced by LPS exposure. The consistency of the quantitative tomography imaging results and its excellent correlation with BAL neutrophil counts show that it is a robust tool for quantifying lung pathology in mouse pulmonary inflammation models.

PDF 448 KB
Non-Invasive Quantitative Tomography of Disease Progression and Therapeutic Response

We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.

PDF 581 KB

Technical Note

ProSense 680 (Protocol)

APP_Protocol_ProSense 680 Activatable Fluorescent imaging agent Protocol

PDF 256 KB
ProSense® 680 (Data Sheet)

ProSense® 680 is a protease activatable fluorescent in vivo imaging agent that is activated by key disease associated proteases such as Cathepsin B, L, S and Plasmin. ProSense 680 is optically silent in its unactivated state and becomes highly fluorescent following protease-mediated activation.


White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB